Redeye comments on the clinical data from the SESAR study and the confusion it brought.
Redeye returns with a more in-depth take on Sedana Medical’s Q4 report.
Redeye returns to covering Sedana Medical and presents its preview for the company’s Q4 report, which is due on February 13.
Redeye lowers its fair value range following a reconsideration of its financial estimates (following the shifted US launch timeline) and an ...
Redeye sees that the Q3 financials were not too far from our estimates (though we were slightly too optimistic), and we are curious about it...
Redeye presents its preview of Sedana Medical’s Q3 2024 report, due October 24.
Redeye notes a weak Q2 for Sedana Medical, with lower sales and higher costs than we expected.
Redeye provides an initial take on Sedana Medical’s Q2 results, and we will return with a more in-depth take on the report.
Redeye presents its preview of Sedana Medical’s Q2 2024 report, due on July 23.
Redeye repeats its view on Sedana Medical’s 2024 sales growth target to be conservative, as is demonstrated by the Q1 sales.
Redeye presents its preview of Sedana Medical’s Q1 2024 report, due on April 25.
Redeye believes 2024 could better demonstrate Sedana Medical’s European expansion and increase the confidence in the US part of the equity s...
Redeye notes that Sedana Medical’s Q4 report showed higher sales than our estimates, though EBITDA was fairly in line with our expectations.
Redeye shares its preview of Sedana Medical’s Q4 2023e results, due February 15.
Redeye returns with an updated take on the Q3 report.
Redeye provides its initial comment on Sedana Medical’s Q3 report.
Redeye shares its preview of Sedana Medical’s Q3 2023e results, due October 26.
Redeye expects the first sales of Sedaconda in the UK by year-end, following today’s full UK approval of Sedana Medical’s inhalation sedatio...
Redeye lowers its sales estimates on all time horizons for Sedana Medical following the Q2 report, rendering downward changes to our fair va...
Redeye provides an initial take on Sedana Medical’s Q2 results, and we will return with updated estimates as the company has given an estima...
Redeye lowers its fair value range following the updated FDA timeline, which will likely hold the share back from any sustainable positive m...
Redeye argues that the ISOCOMFORT study results do not raise any concerns for its market outlook, and we reiterate our SEK88 base case.
Redeye returns with a more detailed take on Sedana Medical’s Q1 report, and we see signs of improved operational development.
Redeye provides an initial take on Sedana Medical’s Q1 results, and we are glad to see our estimates beaten on sales and OPEX.
Redeye shares its preview of Sedana Medical’s Q1 2023e results, due on February 16.
Redeye provides an initial take on Sedana Medical’s Q4 results, and we are optimistic about the sales coming in 12% above our forecast and i...
Redeye shares its preview of Sedana Medical’s Q4 2022 results, due on February 16.
Redeye embraces the FDA Fast Track Designation for the evaluation process of Sedana Medical’s solution for inhaled sedation.
Redeye argues that Sedana Medical may be up against a more challenging sales ramp-up than we previously anticipated.
Redeye lowers its full-year sales estimates for 2022E from SEK 180m to SEK 149m and our 2023-2024E sales by 4-8%, following the report.
Redeye reviews its Fair Value Range for Sedana Medical and reconsiders some key assumptions.
Redeye argues that the changed financial target is relatively unaffecting the long-term case for Sedana Medical.
Redeye initiates coverage of Sedana Medical, a medtech/pharma company challenging the standard of care for sedation in intensive care units.
